XAIR
Beyond Air Inc (XAIR)
Healthcare • NASDAQ • $0.51+3.18%
- Symbol
- XAIR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $0.51
- Daily Change
- +3.18%
- Market Cap
- $5.40M
- Trailing P/E
- N/A
- Forward P/E
- -0.31
- 52W High
- $5.84
- 52W Low
- $0.43
- Analyst Target
- $8.67
- Dividend Yield
- N/A
- Beta
- 0.30
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase …
Company websiteResearch XAIR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.